With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.29608-05-7,4-(Piperidin-1-ylmethyl)aniline,as a common compound, the synthetic route is as follows.
Compound 1 (2.0 g, 5.9 mmol) was refluxed for 2 hours in SOCl2. The reaction was cooled to RT and concentrated. The residue was taken up in DCM and concentrated a second time. The residue was then taken up in THF (25 mL) and added dropwise to a solution containing Compound Ik (1.1 g, 5.9 mmol), THF (25 mL) and DIPEA (2.5 mL, 14.4 mmol) at 0 0C. After 30 mins, the reaction was diluted with DCM and washed successively with 10% NH4Cl, water and brine. The organic layer was dried (Na2SO4), then filtered and treated with excess 2M HCl in ether to precipitate Compound 3 as an HCl salt (1.45 g). MS 537, 539 (MH+).
29608-05-7 4-(Piperidin-1-ylmethyl)aniline 846150, apiperidines compound, is more and more widely used in various.
Reference£º
Patent; JANSSEN PHARMACEUTICA, N.V.; WO2006/118749; (2006); A1;,
Piperidine – Wikipedia
Piperidine | C5H11N – PubChem